Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly, But the Right Test Will Hear It
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“Not every antigen speaks loudly…
But the right test will hear it.
In transfusion medicine, one of the most fascinating diagnostic tools we use to unmask hidden ABO subgroups is the Adsorption and Elution Test.
When routine serology says:
‘No antigen detected…’
This test asks again:
‘Are you absolutely sure?’
And sometimes — it finds what others miss.
Why Adsorption and Elution Matters
Some ABO subgroups (like weak A, weak B, A₃, Aₓ) express very low antigen levels on red cells.
These antigens:
- may not react in routine forward grouping
- may remain undetected even after incubation
- can create ABO discrepancies
- can affect transfusion safety if overlooked
That’s where Adsorption and Elution testing becomes powerful.
It helps us detect the hidden antigen behind the silence.
The Principle (Simple but Powerful)
- Red cells are incubated with anti-A or anti-B antibodies
- Weak antigens adsorb (bind) those antibodies
- Bound antibodies are eluted (released) from the cells
- The eluate is tested with A or B pooled cells
- Agglutination confirms the presence of the weak antigen
This confirms what routine testing could not reveal.
When Should You Think About Using It?
Consider Adsorption and Elution testing when:
- Forward and reverse grouping don’t match
- Weak A or weak B subgroup suspected
- Investigating ABO discrepancies
- Testing neonates or immunocompromised patients
- Resolving uncertain pre-transfusion typing
Why This Test Is So Important
Because accurate ABO subgroup identification means:
- safer transfusion decisions
- fewer compatibility surprises
- stronger laboratory confidence
- better patient outcomes
In transfusion medicine, precision saves lives.
Not every antigen shouts.
But with the right technique, we can still hear its voice.
Do you routinely perform Adsorption and Elution testing in your blood bank when resolving subgroup discrepancies?
Let’s learn from each other — Blood Doki”
Other posts featuring Augustina Isioma Ikusemoro on Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week